Clinical Trial Update: Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates the safety and feasibility of combining vorinostat with decitabine in adults with relapsed, refractory, or poor-prognosis hematolog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia with
• Acute Myeloid Leukemia with 11q23 Abnormalities
• Acute Myeloid Leukemia with Del
• Acute Myeloid Leukemia with Inv
• Myelodysplastic Myeloproliferative Neoplasm Unclassifiable
• Myelodysplastic Syndromes

Drugs mentioned

• Dacogen (decitabine)
• Zolinza (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Status: COMPLETED